Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The North American Society for Pediatric Gastroenterology and Nutrition published guidelines for the evaluation of children suspected of being infected with Helicobacter pylori. The stool antigen test for H. pylori, which was recently commercialized in the United States, was evaluated in two high-risk pediatric populations. The results are encouraging but should be interpreted with caution. A number of studies suggest that delayed gastric emptying may accompany a variety of disorders, or may be a cause of vomiting. The outcome of children with dyspeptic symptoms is described, and the results will be helpful in reassuring anxious parents. Studies examining the development of H, K-adenosine triphosphatase in infants and the role of enteric glial cells in infantile hypertrophic pyloric stenosis are discussed. A study of neonates with allergic gastroenteropathy suggests that this disorder may be more common in this age group than generally thought.
 ...
PMID:Gastroduodenal disorders in children. 1703 Dec 11

Istaroxime is a new luso-inotropic compound selected for the treatment of acute heart failure syndromes, which reduces sodium-potassium adenosine triphosphatase (ATPase) activity and stimulates the sarcoplasmic calcium ATPase isoform 2 reuptake function. The aim of this study was to evaluate the safety profile of istaroxime. For this purpose, istaroxime was administered during a 24-hour infusion to conscious dogs with chronic heart failure and to genetically cardiomyopathic BIO TO.2 hamsters for 34 weeks orally. The parameters recorded were arrhythmic events and hemodynamic effects in dogs and mortality in hamsters. In dogs, istaroxime at 1, 3, and 4 microg/kg per min did not trigger arrhythmic events or magnify preexisting events. It increased left ventricular (LV) dP/dtmax (about 50% at 3 microg/kg per min) and LV-dP/dtmax (about 20% at 3 microg/kg per min) without changing heart rate, blood pressure, or double product. At 4 microg/kg per min, istaroxime increased dP/dtmax>100% but induced intense emesis in all animals. In cardiomyopathic hamsters, the dose of 30 mg/kg prolonged the survival rate to 32%. In conclusion, istaroxime seems to be a promising and safe new drug for improving cardiac performance in the failing heart.
 ...
PMID:Istaroxime: a new luso-inotropic agent for heart failure. 1723 2